BeiGene Ltd logo

BeiGene Ltd

HKSE:06160 (Cayman Islands)   Ordinary Shares
HK$ 107.30 (+0.94%) Dec 24
At Loss
P/B:
5.61
Market Cap:
HK$ 155.82B ($ 20.07B)
Enterprise V:
HK$ 141.93B ($ 18.47B)
Volume:
-
Avg Vol (2M):
1.96M
Trade In:
Volume:
-
At Loss
Avg Vol (2M):
1.96M

Business Description

Description
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2023, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 50% of BeiGene's revenue.
Name Current Vs Industry Vs History
Cash-To-Debt 2.45
Equity-to-Asset 0.59
Debt-to-Equity 0.32
Debt-to-EBITDA -1.52
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 3.56
Distress
Grey
Safe
Beneish M-Score -2.36
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 43.45
9-Day RSI 37.72
14-Day RSI 38.41
6-1 Month Momentum % 20.55
12-1 Month Momentum % 10.27

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 1.93
Quick Ratio 1.72
Cash Ratio 1.33
Days Inventory 278.18
Days Sales Outstanding 48.44
Days Payable 223.87

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -4.4
Shareholder Yield % -2.2

Financials (Next Earnings Date:2025-02-26 Est.)

HKSE:06160's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

BeiGene Ltd Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil HK$) 25,895.025
EPS (TTM) (HK$) -4.999
Beta 0.77
Volatility % 48.07
14-Day RSI 38.41
14-Day ATR (HK$) 4.1432
20-Day SMA (HK$) 115.105
12-1 Month Momentum % 10.27
52-Week Range (HK$) 75.45 - 153
Shares Outstanding (Mil) 1,384.09

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

BeiGene Ltd Filings

Filing Date Document Date Form
No Filing Data

BeiGene Ltd Stock Events

Financials Calendars
Event Date Price(HK$)
No Event Data

BeiGene Ltd Frequently Asked Questions

What is BeiGene Ltd(HKSE:06160)'s stock price today?
The current price of HKSE:06160 is HK$107.30. The 52 week high of HKSE:06160 is HK$153.00 and 52 week low is HK$75.45.
When is next earnings date of BeiGene Ltd(HKSE:06160)?
The next earnings date of BeiGene Ltd(HKSE:06160) is 2025-02-26 Est..
Does BeiGene Ltd(HKSE:06160) pay dividends? If so, how much?
BeiGene Ltd(HKSE:06160) does not pay dividend.

Press Release

Subject Date
No Press Release